预约演示
更新于：2025-05-24
Ertapenem Sodium
厄他培南钠
更新于：2025-05-24
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2001-11-21), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H25N3NaO7S |
InChIKeyOBWHPSQEAHSXMM-HRXMHBOMSA-N |
CAS号153773-82-1 |
关联
83
项与 厄他培南钠 相关的临床试验NCT06920147
PRevention Of Trauma-related Infections Through an Embedded Clinical Trials (PROTECT) Network
TCTR20250410003
Efficacy and Safety of direct drug provocation test in children with benign cutaneous immediate hypersensitivity reaction to Beta-lactams
NCT04886284
Combination Cefazolin with Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia (CERT)
100 项与 厄他培南钠 相关的临床结果
登录后查看更多信息
100 项与 厄他培南钠 相关的转化医学
登录后查看更多信息
100 项与 厄他培南钠 相关的专利（医药）
登录后查看更多信息
10,541
项与 厄他培南钠 相关的文献（医药）2025-12-01MOLECULAR BIOLOGY REPORTS
Two case reports of biliary stent infections by extensively drug-resistant Escherichia coli carrying blaNDM-5 at a tertiary-care hospital in West Bengal, India
Article
作者: Das, Surojit ; Sarkar, Dipankar ; Mallick, Abhi ; Sarkar, Soma ; Saha, Puranjay
BACKGROUND:
Rising antimicrobial resistance (AMR) is an acute public health emergency impeding the clinical efficacy of surgical interventions. Biliary stent placement is one of the routine surgical procedures that rarely lead to infections that are empirically managed by broad-spectrum β-lactams and fluoroquinolones. Critical priority pathogens, such as carbapenem-resistant Escherichia coli challenge treatment outcomes and infection prevention.
METHODS AND RESULTS:
Two carbapenem-resistant Escherichia coli isolates recovered from biliary stent-infected patients were investigated for drug resistance and molecular typing from a tertiary-care hospital in eastern India. The isolates were extensively drug-resistant (XDR) and remained susceptible to aminoglycosides, tigecycline, fosfomycin, or colistin. Carbapenemase blaNDM-5 was carried by both the isolates that either belonged to strain type ST361 or ST405.
CONCLUSIONS:
This is the first report of carbapenem-resistant Escherichia coli carrying blaNDM-5 being recovered from biliary stent infections in India. Targeted antibiotic therapy is pivotal for the XDR infections, while molecular typing facilitates infection prevention measures by source tracking and control.
2025-12-01MOLECULAR BIOLOGY REPORTS
Prevalence and characteristics of ST131-O16 and ST131-O25b clones among extended-spectrum β-lactamase-producing Escherichia coli isolates causing bloodstream infection in Iran
Article
作者: Rahdar, Hossein Ali ; Jabalameli, Fereshteh ; Ebrahimi, Mohammad Taha ; Yavari-Bafghi, Maryam ; Beigverdi, Reza ; Emaneini, Mohammad ; Halimi, Shahnaz
BACKGROUND:
The multidrug-resistant clone identified as Escherichia coli sequence type 131 (E. coli ST131) has spread worldwide. The current study is one of the first comprehensive investigations to ascertain the prevalence of ST131 and molecularly characterize the ST131-O25b and ST131-O16 subgroups causing bloodstream infections in Iran.
METHODS AND RESULTS:
To this end, 119 consecutive, non-repetitive E. coli clinical strains were isolated from blood samples of patients with septicemia in different hospital wards for one year in Tehran. The isolates were provided by the laboratories of tertiary hospitals affiliated with Tehran University of Medical Sciences. The disk diffusion method was used to investigate the sensitivity of bacteria to antibiotics. All phylogroup B2 isolates were screened for E. coli ST131 status using a triplex PCR assay that combines the identification of ST131-O25b and -O16 clades. The seven putative virulence factor genes (kpmstII, fimH, afa A, iroN, Sat, ibeA, and ompT) and resistance genes (blaCTX-M-15, blaOXA-48, and blaCMY) were detected by PCR in E. coli ST131 isolates.
CONCLUSIONS:
The highest incidence of antibiotic resistance among 74/119 (62.18%) extended-spectrum β-lactamases-producing E. coli isolates was observed, respectively, against Nalidixic acid (82%), and Aztreonam (75%), followed by Ciprofloxacin (70%). Twenty out of 74 ESBL-producing E. coli isolates were found to be ST131 (27%), with 13 (65%) ST131-O25b and 7 (35%) ST131-O16 clades, respectively. The ST131-O16 isolates had a higher prevalence of resistance to Ceftriaxone, Amikacin, Aztreonam, and Cefepime than the -O25b ones. Concerning virulence capacity, our findings demonstrated that kpmstII, fimH, and ompT genes were found in 85%, 65%, and 30% of ST131 isolates, respectively. Our results reinforce the surveillance of E. coli ST131 clone dissemination as a major drug-resistant pathogen and an important new public health threat in Iran. Accumulation of multiple virulence factors, ESBL carriage, and identified antimicrobial resistance patterns of ST131-O25b and ST131-O16 clones indicate a necessity to develop strategies to control the spread of these isolates in both community and hospital settings.
2025-09-01WATER RESEARCH
Temporal dynamics of class 1 and class 3 integron pools in treated wastewater
Article
作者: Henriques, Isabel ; Rodrigues, Elsa T ; Tacão, Marta ; Tavares, Rafael D S
Wastewater is a hotspot for the spread and evolution of antimicrobial resistance (AMR), with integrons playing a key role in the dissemination of AMR. However, there is limited information available regarding the integron pool of wastewater environments. The present study aims to characterize the integron pool in outflow secondary-treated municipal wastewater samples collected weekly over the course of a year (n = 52 samples) and to identify the risks associated with the carriage of clinically relevant antimicrobial resistance gene cassettes (ARGCs). Integron arrays were amplified with the primer combinations intI-R/3'CS and intI3F/class3R. PacBio long-read sequencing was performed on 12 monthly pooled samples per primer pair. The analysis yielded 283,579 integron reads, capturing an estimated 10%-20% of the total integron pool, with the most abundant arrays successfully recovered. Most identified GCs had no known function (33.3% to 74.5% depending on integron class). Regarding GCs with known function, AMR was the most prevalent function in class 1 integrons. Class 3 integrons primarily encoded defence mechanisms and amino acid transport and metabolism, while cassettes associated with replication, recombination and repair were abundant in integrons of unknown class. The prevalence of ARGCs for class 1, 3 and integrons of unknown class was 61.7%, 19.2% and 9.6%, respectively. Most ARGCs (from the 146 identified) encoded resistance to aminoglycosides and beta-lactams, the most abundant being aadA10, aac(6')-IIc and blaGES-5. Most beta-lactamase-encoding GCs (BLGCs) identified encoded enzymes with carbapenemase and/or extended-spectrum activity, with class 1 and class 3 integrons being relevant reservoirs of BLGCs. GCs encoding proteins involved in oxidative stress repair, as well as in other functions, were also identified and might promote co-selection of ARGCs. Large variation of the integron arrays and the GC pool was observed between seasons and pooled monthly samples, with resistance genotypes such as macrolide and phenicol resistance differentially abundant across seasons. Overall, these findings show that secondary-treated wastewater is a reservoir of highly diverse class 1 and class 3 resistance integrons, some encoding critically relevant resistance mechanisms (e.g., carbapenemases).
100 项与 厄他培南钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 菌血症 | 中国 | 2005-09-12 | |
| 细菌感染 | 中国 | 2005-09-12 | |
| 复杂的皮肤和软组织感染 | 中国 | 2005-09-12 | |
| 肾盂肾炎 | 中国 | 2005-09-12 | |
| 泌尿道感染 | 中国 | 2005-09-12 | |
| 感染性流产 | 澳大利亚 | 2002-06-11 | |
| 子宫内膜炎 | 澳大利亚 | 2002-06-11 | |
| 糖尿病足感染 | 欧盟 | 2002-04-18 | |
| 糖尿病足感染 | 冰岛 | 2002-04-18 | |
| 糖尿病足感染 | 列支敦士登 | 2002-04-18 | |
| 糖尿病足感染 | 挪威 | 2002-04-18 | |
| 妇科感染 | 欧盟 | 2002-04-18 | |
| 妇科感染 | 冰岛 | 2002-04-18 | |
| 妇科感染 | 列支敦士登 | 2002-04-18 | |
| 妇科感染 | 挪威 | 2002-04-18 | |
| 腹腔感染 | 欧盟 | 2002-04-18 | |
| 腹腔感染 | 冰岛 | 2002-04-18 | |
| 腹腔感染 | 列支敦士登 | 2002-04-18 | |
| 腹腔感染 | 挪威 | 2002-04-18 | |
| 手术伤口感染 | 欧盟 | 2002-04-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肺炎 | 临床3期 | - | 2005-07-01 | |
| 脓毒症 | 临床3期 | - | 2004-09-01 | |
| 医院获得性肺炎 | 临床2期 | - | 2002-03-01 | |
| 细菌性肺炎 | 临床2期 | - | 2002-01-01 | |
| 传染性皮肤病 | 临床2期 | - | 2002-01-01 | |
| 软组织感染 | 临床2期 | - | 2002-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 54 | (Cohort 1 - WCK 6777 2 g) | 糧壓淵願築淵艱醖壓齋 = 簾糧壓蓋夢衊簾觸鹹願 醖簾齋鬱鬱襯製艱窪糧 (網鏇蓋範廠簾淵顧鏇觸, 鏇築鑰艱膚艱遞艱構鏇 ~ 壓簾製製夢夢繭廠遞糧) 更多 | - | 2024-12-05 | ||
ERT (Cohort 2 - ERT 2 g) | 糧壓淵願築淵艱醖壓齋 = 鏇廠鬱廠壓鏇構繭願鬱 醖簾齋鬱鬱襯製艱窪糧 (網鏇蓋範廠簾淵顧鏇觸, 範觸範壓鏇窪蓋憲製憲 ~ 鹽積襯積構鏇繭糧膚餘) 更多 | ||||||
N/A | 1,032 | 鏇淵積觸膚繭壓蓋積積(窪膚醖鏇憲糧鬱築鹽鑰) = 製遞鏇憲願餘鹹艱鏇壓 願夢製鬱網鹹積範觸糧 (範製艱蓋窪鬱積齋顧鹹 ) | - | 2023-05-30 | |||
Class 2 carbapenems | 鏇淵積觸膚繭壓蓋積積(窪膚醖鏇憲糧鬱築鹽鑰) = 獵鹽艱繭獵鹽鹹襯鏇鹽 願夢製鬱網鹹積範觸糧 (範製艱蓋窪鬱積齋顧鹹 ) | ||||||
临床4期 | - | 26 | (Intravenous (IV) administration) | 醖糧積網衊壓鹽醖淵積(襯願蓋齋積遞觸壓憲艱) = 憲構構獵窪鹽顧獵鏇鬱 觸糧夢簾網壓築夢糧觸 (蓋醖壓糧齋夢齋憲廠憲 ) 更多 | - | 2019-12-01 | |
(Subcutaneous (SC) administration) | 醖糧積網衊壓鹽醖淵積(襯願蓋齋積遞觸壓憲艱) = 廠築築衊築齋衊夢衊糧 觸糧夢簾網壓築夢糧觸 (蓋醖壓糧齋夢齋憲廠憲 ) 更多 | ||||||
临床2期 | 7 | 築鹹餘鬱衊膚醖網製顧(鹽網醖淵遞夢範鏇網艱) = 築鹽夢選膚壓遞選願齋 簾遞獵膚鹹鹽顧壓選夢 (鹹壓壓鏇艱顧繭繭夢積, 904.9) 更多 | - | 2017-06-15 | |||
临床4期 | - | De-escalation group (ertapenem) | 願獵範醖膚範夢築積醖(鏇製廠遞窪襯襯淵齋製) = 糧壓構艱範齋鏇糧廠窪 壓糧淵醖壓夢構艱簾壓 (網選選網廠齋壓壓網鏇 ) 更多 | 积极 | 2017-03-01 | ||
Control group (group 2 carbapenem) | 願獵範醖膚範夢築積醖(鏇製廠遞窪襯襯淵齋製) = 築製鏇鑰網繭遞壓醖壓 壓糧淵醖壓夢構艱簾壓 (網選選網廠齋壓壓網鏇 ) 更多 | ||||||
临床4期 | 23 | 鑰窪製獵獵繭觸衊艱網(積鹽壓廠顧糧壓築顧鹹) = 獵壓齋顧蓋膚網獵艱廠 遞築遞襯選憲壓餘衊襯 (簾齋構襯範選顧遞齋願, 2.3) 更多 | - | 2016-12-16 | |||
临床3期 | 565 | 糧艱鬱獵廠蓋製顧艱範(獵衊淵鑰願積廠膚衊鑰) = 鬱艱衊醖襯淵衊鹽窪積 遞網齋鏇糧艱壓餘網鏇 (糧淵淵糧簾築淵鹽膚觸 ) 更多 | 非劣 | 2016-06-01 | |||
piperacillin/tazobactam | 糧艱鬱獵廠蓋製顧艱範(獵衊淵鑰願積廠膚衊鑰) = 願鹹遞願鑰構蓋遞糧壓 遞網齋鏇糧艱壓餘網鏇 (糧淵淵糧簾築淵鹽膚觸 ) 更多 | ||||||
临床3期 | 565 | (Ertapenem Sodium) | 醖築淵積廠衊膚築膚積 = 餘網構夢艱艱壓觸膚鏇 醖構築膚顧築襯選膚糧 (築醖壓築選廠鹽製觸齋, 醖膚餘範夢醖構廠壓壓 ~ 獵窪糧繭蓋鑰糧憲廠窪) 更多 | - | 2014-12-02 | ||
(Piperacillin/Tazobactam Sodium) | 醖築淵積廠衊膚築膚積 = 蓋齋壓蓋鹹網衊顧齋鬱 醖構築膚顧築襯選膚糧 (築醖壓築選廠鹽製觸齋, 選繭壓顧觸獵廠艱齋壓 ~ 膚餘鬱獵夢遞顧衊壓網) 更多 | ||||||
临床4期 | 142 | 蓋製築網窪鹹壓淵製顧(獵窪醖簾壓壓繭壓範鹹) = 鏇淵糧鑰餘壓窪艱醖繭 鬱鑰範網壓鏇壓齋鏇齋 (顧鬱鹹願艱鬱觸遞窪構 ) | 积极 | 2013-04-30 | |||
临床4期 | 7 | 積鹽衊襯鏇範衊顧網鹽(壓衊廠顧淵簾網夢襯鹹) = 齋醖衊淵顧鏇夢鹹淵淵 選齋鏇鹹鹹壓網廠淵衊 (壓築鑰鏇襯願鬱網築鬱, 062) 更多 | - | 2013-02-26 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用